Deutsche Bank
KNSA icon

Deutsche Bank’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Deutsche Bank’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.2M Sell
523,691
-106,600
-17% -$4.72M 0.01% 794
2025
Q4 		$26M Buy
630,291
+96,916
+18% +$3.89M 0.01% 810
2025
Q3 		$20.7M Buy
533,375
+163,873
+44% +$5.32M 0.01% 847
2025
Q2 		$10.2M Sell
369,502
-25,020
-6% -$637K ﹤0.01% 990
2025
Q1 		$8.76M Buy
394,522
+252,125
+177% +$5.19M ﹤0.01% 1043
2024
Q4 		$2.82M Buy
142,397
+62,083
+77% +$1.42M ﹤0.01% 1639
2024
Q3 		$2.01M Buy
+80,314
New +$1.96M ﹤0.01% 1738
2024
Q2 		– Sell
-91,744
Closed -$1.81M – 3633
2024
Q1 		$1.81M Buy
91,744
+385
+0.4% +$7.52K ﹤0.01% 1718
2023
Q4 		$1.6M Sell
91,359
-367
-0.4% -$6.03K ﹤0.01% 1793
2023
Q3 		$1.59M Buy
91,726
+2,220
+2% +$37.4K ﹤0.01% 1468
2023
Q2 		$1.26M Sell
89,506
-9,069
-9% -$121K ﹤0.01% 1857
2023
Q1 		$1.06M Buy
98,575
+23,316
+31% +$307K ﹤0.01% 2064
2022
Q4 		$1.13M Sell
75,259
-1,053
-1% -$15.3K ﹤0.01% 1977
2022
Q3 		$980K Buy
76,312
+84
+0.1% +$957 ﹤0.01% 1980
2022
Q2 		$739K Sell
76,228
-1,430
-2% -$13.3K ﹤0.01% 2363
2022
Q1 		$772K Sell
77,658
-2,709
-3% -$28.7K ﹤0.01% 2501
2021
Q4 		$946K Buy
80,367
+1,255
+2% +$15.4K ﹤0.01% 2468
2021
Q3 		$901K Sell
79,112
-543
-0.7% -$7.07K ﹤0.01% 2688
2021
Q2 		$1.11M Sell
79,655
-35,980
-31% -$547K ﹤0.01% 2705
2021
Q1 		$2.14M Buy
115,635
+90,931
+368% +$1.86M ﹤0.01% 2123
2020
Q4 		$436K Buy
24,704
+9,452
+62% +$166K ﹤0.01% 2997
2020
Q3 		$233K Buy
15,252
+5,136
+51% +$96.4K ﹤0.01% 3136
2020
Q2 		$257K Buy
10,116
+5,425
+116% +$113K ﹤0.01% 3014
2020
Q1 		$72K Sell
4,691
-282
-6% -$4.41K ﹤0.01% 3387
2019
Q4 		$54K Buy
4,973
+1,121
+29% +$9.74K ﹤0.01% 3935
2019
Q3 		$31K Sell
3,852
-5,707
-60% -$63.1K ﹤0.01% 4152
2019
Q2 		$127K Sell
9,559
-4,205
-31% -$65.2K ﹤0.01% 4079
2019
Q1 		$246K Buy
13,764
+6,783
+97% +$131K ﹤0.01% 3886
2018
Q4 		$195K Sell
6,981
-7,716
-53% -$161K ﹤0.01% 3885
2018
Q3 		$374K Buy
+14,697
New +$286K ﹤0.01% 3935

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Deutsche Bank's KNSA Position: Q1 2026 in Review

Deutsche Bank reduced its Kiniksa Pharmaceuticals (KNSA) stake by 17% in Q1 2026, selling an estimated $4.72M and leaving 523,691 shares worth $25.2M. The position accounts for 0.01% of the portfolio, ranked #794.

Deutsche Bank first reported a position in KNSA in Q3 2018 and has held it in 30 quarters since. The position peaked at $26M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Deutsche Bank held 523,691 shares of Kiniksa Pharmaceuticals worth $25.2M as of Q1 2026.
  • Deutsche Bank sold 106,600 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $4.72M.
  • Kiniksa Pharmaceuticals made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #794 holding.
  • Deutsche Bank first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
  • Deutsche Bank's Kiniksa Pharmaceuticals position peaked at $26M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.